Core Viewpoint - Northeast Pharmaceutical has demonstrated a notable performance in quality transformation through structural adjustments in the first quarter of 2025, despite a slight revenue increase of only 0.36% [1] Group 1: Financial Performance - The company achieved a 20.5% year-on-year reduction in sales expenses and a simultaneous decrease in management expenses, while strategically increasing R&D expenses to 32 million yuan, an 88% year-on-year surge [2] - As of the end of the first quarter, the company's debt-to-asset ratio decreased to 58.82%, down 2.63 percentage points from the beginning of the year, indicating improved financial health and reduced short-term repayment risks [2] Group 2: Innovation and R&D - Northeast Pharmaceutical is implementing a dual-driven strategy of "innovative drugs + generic drugs," covering multiple therapeutic areas including the nervous system, digestive system, and oncology, which highlights its long-term growth potential [3] - The company has accelerated its strategic layout in cutting-edge fields of innovative drugs, with a significant increase in R&D funding aimed at tumor immunotherapy, a key trend in the global pharmaceutical industry [3] - The company has developed over 10 targeted cell immunotherapy products for various cancers, with DCTY1102 injection expected to be the first TCR-T cell drug targeting KRAS G12D to enter Phase I clinical trials in China [3] Group 3: Competitive Strategy - The company has consolidated its competitive advantage through a "combination of innovation and imitation" strategy, with 243 product specifications included in the national medical insurance catalog and 120 in the national essential drug list, providing a stable foundation for performance growth [4] - This dual-driven model of "innovative drugs leading and generic drugs supporting" ensures short-term performance certainty while opening up long-term growth opportunities [4] Group 4: Global Strategy - The company is leveraging its international gene advantage to enhance its global sales network, with its leading products exported to over 100 countries and regions, thereby diversifying market risks and creating sustainable revenue streams [5] - Despite short-term profit fluctuations, the company's strategic transformation is showing initial results, with management reforms and future-oriented R&D investments leading to significant improvements in operational quality [5] - As the innovative drug pipeline matures and the global strategy deepens, Northeast Pharmaceutical is transitioning from a traditional pharmaceutical company to a leader in biotechnology, with the commercialization of cell therapies expected to initiate a new growth cycle [5]

1.1 摘要 透明质酸是存在于人体的天然成分，其在食品领域的应用产品就是透明质酸食品，属 于保健食品的新兴赛道。受上游透明质酸原料的技术突破与产能释放，国产品牌在透 明质酸食品市场的竞争中占据有利地位。透明质酸食品的推出顺应居民美容健康意识 提升的趋势，在科研创新的推动下，预计中国食品级透明质酸终端产品的市场规模将 持续增长。 1.2 透明质酸食品定义 2025 年透明质酸食品品牌推荐 银发经济持续升温，功能性食品产业 迎来重要催化 目录 | 一、市场背景 ……………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………… 3 | | --- | | 1.1 摘要 … | | 1.2 透明质酸食品定义 . | | 1.3 市场演变 | | 市场现状 . | | 2.1 市场规模 | | 2.2 市场供需 … | | 三、市场竞争 ………………………………………………………………………………………………………………………………………………………………… ...

Core Viewpoint - The company, Northeast Pharmaceutical Group Co., Ltd., has disclosed its quarterly report, ensuring the accuracy and completeness of the financial information presented, and has not undergone an audit for this report [1][2][13]. Financial Data Summary - The company reported a significant increase in other current assets, with a year-end balance of 34.68 million yuan, reflecting a 31% growth compared to the beginning of the year, primarily due to changes in tax payments [4]. - The balance of notes payable decreased to 2.05 billion yuan, a reduction of 42% from the beginning of the year, attributed to a decrease in issued notes [5]. - The payable to employees dropped to 2.62 million yuan, down 94% from the beginning of the year, due to a reduction in employee compensation [5]. - The balance of taxes payable was 54.97 million yuan, a decrease of 31% from the beginning of the year, influenced by tax payments made during the period [5]. - Research and development expenses amounted to 32 million yuan, an increase of 88% year-on-year, indicating a higher investment in R&D [5]. - Financial expenses were reported at -7.68 million yuan, a decrease of 32% year-on-year, due to reduced interest expenses on bank loans [5]. - Investment income was 1.35 million yuan, down 41% year-on-year, primarily due to a decrease in debt restructuring amounts [5]. - The company reported a significant reduction in credit impairment losses, amounting to -5.87 million yuan, a decrease of 2380% year-on-year, due to an increase in accounts receivable [5]. - The asset impairment loss was -64.44 million yuan, a decrease of 71% year-on-year, attributed to an increase in inventory write-down provisions [5]. - The company recorded a net cash inflow from the disposal of fixed assets of 30,000 yuan, a decrease of 92% year-on-year, indicating reduced cash recovery from asset disposals [8]. - Cash received from bank borrowings was 14.4 billion yuan, an increase of 157% year-on-year, reflecting higher bank loan receipts [9]. - Cash paid for debt repayment was 9.92 billion yuan, an increase of 183% year-on-year, due to increased cash outflows for loan repayments [9]. Legal Matters - The company is involved in a legal dispute with a claim for economic damages of 32.7 million yuan and additional interest losses of approximately 25.15 million yuan, totaling 57.85 million yuan [15][16]. - The case has been accepted by the court and is scheduled for a hearing on May 12, 2025 [17]. - The company has stated that there are no other undisclosed significant litigation or arbitration matters as of the announcement date [18].

Core Viewpoint - Northeast Pharmaceutical's integration of "raw materials + formulations" establishes a solid foundation for sustainable development and enhances its competitiveness in the pharmaceutical market [1] Group 1: Innovation and R&D - The company is a significant drug production and export base in China, continuously increasing its investment in new product development, with a projected 7.55% growth in R&D investment for 2024 [2] - Northeast Pharmaceutical has formed a collaborative R&D network across Shenyang, Beijing, and Shanghai, improving R&D efficiency and accelerating the market launch of new products [2][3] - The company has approved the production of 5 generic drugs and has 6 innovative drugs entering clinical research in 2024, with a focus on cell therapy following the acquisition of a 70% stake in Dingcheng Peptide Source [2][3] Group 2: AI and Management Efficiency - The company has initiated a deep application of artificial intelligence (AI) to enhance management efficiency, identifying optimization points in production and reducing energy costs by 30,000 yuan per month on one production line [4][5] - AI applications have improved market response speed and operational quality, contributing to the company's transformation into an innovative international pharmaceutical group [5] Group 3: Market Position and Product Structure - Northeast Pharmaceutical has developed a comprehensive product structure covering ten major categories, including vitamins, anti-infectives, and oncology treatments, while optimizing its marketing system [6] - The company aims to meet the increasing public demand for quality and new drugs by leveraging its integrated advantages in raw materials and formulations, while actively entering the biopharmaceutical sector [6][7] Group 4: Cell Therapy Development - The acquisition of Dingcheng Peptide Source allows Northeast Pharmaceutical to develop a range of cell therapy products targeting various cancers, with a focus on TCR-T cell products [7] - The company plans to accelerate the development of its biopharmaceutical pipeline, aiming for significant progress in 2024 [7]

证券代码：000597 证券简称：东北制药 公告编号：2025-041 经内蒙古自治区乌海市海南区人民法院审查认为，本案情复杂，裁定转为普 通程序。本案定于2025年5月12日开庭审理。 东北制药集团股份有限公司 诉讼进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 一、本次诉讼事项的基本情况 东北制药集团股份有限公司（以下简称"东北制药"或"公司"）于近日收 到乌海市海南区人民法院《传票》〔（2025）内0303民初687号〕及相关法律文 书。原告乌海市海南区双清农牧业开发有限责任公司（以下简称"乌海双清"） 诉被告东北制药、东药乌海化工有限公司（以下简称"乌海化工"），第三人北 京华德停车场管理有限公司（以下简称"北京华德"）合同纠纷一案（以下简 称"本案"），已由内蒙古自治区乌海市海南区人民法院立案受理。 主要请求事项为： 1.请求依法判令被告东北制药集团股份有限公司与被告东药乌海化工有限公 司共同赔偿原告经济损失32,700,000元。 2.请求依法判令二被告共同赔偿违约利息损失25,145,180.14元。（违约利 息损失以32,700,00 ...

Financial Performance - The company's revenue for Q1 2025 was CNY 1,947,277,598.78, a slight increase of 0.36% compared to CNY 1,940,260,731.63 in the same period last year[5]. - Net profit attributable to shareholders decreased by 36.98% to CNY 36,321,572.23 from CNY 57,633,861.05 year-on-year[5]. - Total operating revenue for the current period reached ¥1,947,277,598.78, a slight increase from ¥1,940,260,731.63 in the previous period, reflecting a growth of approximately 0.09%[21]. - Net profit for the current period was ¥35,371,414.93, down from ¥59,781,000.10 in the previous period, representing a decline of approximately 40.19%[22]. - The total comprehensive income for the current period was ¥35,312,945.96, down from ¥59,847,129.06 in the previous period, indicating a decrease of approximately 41.00%[23]. Cash Flow - The net cash flow from operating activities was negative at CNY -30,857,306.06, a decline of 132.52% compared to CNY 94,887,495.36 in the previous year[5]. - Cash generated from operating activities was ¥1,512,950,908.83, a decrease from ¥1,698,161,792.76 in the previous period, indicating a decline of about 10.92%[25]. - The net cash flow from operating activities was -30,857,306.06, a decrease from 94,887,495.36 in the previous period[26]. - Cash inflow from financing activities totaled 3,253,729,501.82, compared to 2,168,604,450.25 previously, indicating a significant increase[26]. - Cash outflow for financing activities was 3,317,380,209.04, compared to 1,967,909,321.94 previously, reflecting increased financial obligations[26]. Assets and Liabilities - Total assets decreased by 5.78% to CNY 13,611,193,970.86 from CNY 14,446,181,851.25 at the end of the previous year[5]. - Total current assets amount to 7,941,156,174.05 RMB, down from 8,646,485,795.58 RMB[18]. - Total non-current assets amount to 5,670,037,796.81 RMB, down from 5,799,696,055.67 RMB[18]. - Total liabilities decreased to ¥8,006,283,075.57 from ¥8,876,538,951.68, a reduction of about 9.78%[19]. Shareholder Information - Total number of common shareholders at the end of the reporting period is 60,559[16]. - Jiangxi Fangda Steel holds 31.01% of shares, totaling 443,231,442 shares, with 285,062,211 shares pledged[16]. - Liaoning Fangda Group holds 23.03% of shares, totaling 329,068,713 shares, with no shares pledged[16]. Research and Development - R&D expenses increased by 88% to CNY 32,000,000 compared to the same period last year, indicating a significant investment in new product development[9]. - Research and development expenses increased to ¥31,999,540.39 from ¥17,035,942.04, marking an increase of approximately 88.50%[22]. Other Financial Metrics - The weighted average return on equity fell to 0.68% from 1.15% year-on-year, reflecting a decline in profitability[5]. - Earnings per share (basic and diluted) decreased to ¥0.025 from ¥0.040, reflecting a reduction of 37.50%[23]. - The company reported a net loss from credit impairment of ¥5,872,091.65, compared to a gain of ¥257,502.93 in the previous period[22]. - The company recorded a total of CNY 16,414,574.75 in non-recurring gains, primarily from government subsidies and debt restructuring[6]. Donations and Social Responsibility - The company donated 10 million RMB to earthquake relief efforts in Tibet[17].

证券代码：000597 证券简称：东北制药 公告编号：2025-039 东北制药集团股份有限公司 2024 年度股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 特别提示： 1．本次股东大会未出现否决议案的情形； 4．公司独立董事在本次年度股东大会上进行了述职。 一、会议召开和出席情况 （一）会议召开情况 1.本次会议召开的时间： （1）现场会议召开时间：2025 年 4 月 24 日 14:00 （2）网络投票时间：通过深圳证券交易所系统进行网络投票的具体时间为 2025 年 4 月 24 日 9:15 至 9:25，9:30 至 11:30，13:00 至 15:00；通过深圳证券 交易所互联网投票系统进行网络投票的具体时间为 2025 年 4 月 24 日 9:15 至 15:00。 2.现场会议地点：沈阳经济技术开发区昆明湖街 8 号，东北制药集团股份有 限公司。 3.召开方式：采用现场表决与网络投票相结合的方式召开。 4.召集人：公司董事会 5.主持人：公司董事长周凯先生 6.本次股东大会会议召开符合有关法律、行政法规、部门规章、规范 ...

证券代码：000597 证券简称：东北制药 公告编号：2025-038 东北制药集团股份有限公司 第十届监事会第一次会议决议公告 1.东北制药集团股份有限公司（以下简称"公司"）第十届监事会第一次会 议于 2025 年 4 月 18 日发出会议通知，于 2025 年 4 月 24 日以通讯表决的方式召 开。 2.会议应参加监事 3 人，实际参加监事 3 人。 3.本次会议的召集、召开和表决程序符合有关法律、行政法规、部门规章、 规范性文件和《东北制药集团股份有限公司章程》的规定，会议形成的决议合法 有效。 二、监事会会议审议情况 会议审议并以记名投票表决方式通过以下议案： 议案：关于选举公司第十届监事会主席的议案 同意选举詹柏丹女士担任公司第十届监事会主席（简历详见附件），任期自 本次监事会审议通过之日起至第十届监事会届满之日止。 表决结果：同意 3 票，反对 0 票，弃权 0 票。 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 一、监事会会议召开情况 特此公告。 1 东北制药集团股份有限公司监事会 2025 年 4 月 25 日 2 附件：公司监事会主席简 ...

第十届董事会第一次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 证券代码：000597 证券简称：东北制药 公告编号：2025-037 东北制药集团股份有限公司 1.东北制药集团股份有限公司（以下简称"公司"）第十届董事会第一次会 议于 2025 年 4 月 18 日发出会议通知，于 2025 年 4 月 24 日以通讯表决的方式召 开。经全体董事共同推举，本次会议由董事周凯先生主持。 2.会议应参加董事 11 人，实际参加董事 11 人。 3.本次会议的召集、召开和表决程序符合有关法律、行政法规、部门规章、 规范性文件和《东北制药集团股份有限公司章程》的规定，会议形成的决议合法 有效。 二、董事会会议审议情况 一、董事会会议召开情况 会议审议并以记名投票表决方式通过以下议案： 议案一：关于选举公司第十届董事会董事长的议案 同意选举周凯先生（简历详见附件）为公司第十届董事会董事长，任期自本 次董事会审议通过之日起至第十届董事会届满之日止。 表决结果：同意 11 票，反对 0 票，弃权 0 票。 议案二：关于选举公司第十届董事会专门委员会委员的议 ...

北京德恒律师事务所 关于东北制药集团股份有限公司 2024 年度股东大会的 法律意见 北京市西城区金融街 19 号富凯大厦 B 座 12 层 电话：010-52682888 传真：010-52682999 邮编：100033 法律意见 北京德恒律师事务所 关于东北制药集团股份有限公司 2024 年度股东大会的法律意见 北京德恒律师事务所 关于东北制药集团股份有限公司 2024 年度股东大会的 法律意见 德恒 01G20240159 号 为出具本法律意见，德恒律师出席了本次会议，并审查了公司提供的以下文 件，包括但不限于： （一）《公司章程》； （二）董事会决议及相关股东大会审议的议案； （三）公司于 2025 年 4 月 3 日在巨潮资讯网（http：//www.cninfo.com.cn） 公布的《东北制药集团股份有限公司关于召开 2024 年度股东大会的通知》以及 2025 年 4 月 18 日在巨潮资讯网公布的《东北制药集团股份有限公司关于取消 2024 年度股东大会部分议案暨补充通知的公告》（以下统称"《股东大会的通 知》"）； （四）公司本次会议现场参会股东到会登记记录及凭证资料； （五）公司本次会 ...